Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report
High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20-40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
ABV-press,
2019-07-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a348c7f5ea9d4a4281f92fd527f8ffb7 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a T. T. Andabekov |e author |
| 700 | 1 | 0 | |a M. K. Rodina |e author |
| 700 | 1 | 0 | |a G. A. Raskin |e author |
| 700 | 1 | 0 | |a K. G. Cham |e author |
| 700 | 1 | 0 | |a I. O. Rutkin |e author |
| 245 | 0 | 0 | |a Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report |
| 260 | |b ABV-press, |c 2019-07-01T00:00:00Z. | ||
| 500 | |a 1994-4098 | ||
| 500 | |a 1999-8627 | ||
| 500 | |a 10.17650/1994-4098-2019-15-1-73-77 | ||
| 520 | |a High efficacy of anti-PD-1 therapy has been shown in malignant tumors with mismatch repair deficiency. According to the literature review, mismatch repair deficiency is determined in 20-40 % of all endometrial cancer cases and up to 48 % of its endometrioid subtype. We report the short review of the recent literature and the case of durable partial response on pembrolizumab immunotherapy in a patient with a metastatic endometrioid adenocarcinoma with MMR-deficiency progressed on 2 chemotherapy lines. Partial response was achieved after 6th course, treatment was stopped after 8th course. Patient is on follow-up without any anticancer treatment for 11 months. Partial response lasts for 13 months, with further reduction in tumor size. The treatment was well tolerated without adverse events. | ||
| 546 | |a RU | ||
| 690 | |a endometriоid adenocarcinoma | ||
| 690 | |a endometrial carcinoma | ||
| 690 | |a dmmr | ||
| 690 | |a msi-h | ||
| 690 | |a immunotherapy | ||
| 690 | |a pd-1 inhibitor | ||
| 690 | |a pembrolizumab | ||
| 690 | |a Gynecology and obstetrics | ||
| 690 | |a RG1-991 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Опухоли женской репродуктивной системы, Vol 15, Iss 1, Pp 73-77 (2019) | |
| 787 | 0 | |n https://ojrs.abvpress.ru/ojrs/article/view/636 | |
| 787 | 0 | |n https://doaj.org/toc/1994-4098 | |
| 787 | 0 | |n https://doaj.org/toc/1999-8627 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a348c7f5ea9d4a4281f92fd527f8ffb7 |z Connect to this object online. |